CE Mark for Symmetry vagus nerve stimulation therapy to treat depression. - LivaNova PLC
Related news and insights
Sage Therapeutics, Inc. and Biogen Inc. initiated a rolling submission of a New Drug Application (NDA) to the FDA for zuranolone in the treatment of major depressive disorder (MDD).
H. Lundbeck A/S (Lundbeck) recently completed a global Phase IV, randomized, comparative study exploring the role of vortioxetine as a treatment option between SSRIs and serotonin–noradrenaline reuptake inhibitors (SNRIs).
AbbVie announced that it has submitted a supplemental New Drug Application (sNDA) for cariprazine (Vraylar) to the FDA for the adjunctive treatment of major depressive disorder (MDD) in patients who are receiving ongoing antidepressant therapy.